TQ19 : PD-L1 (SP142) TECENTRIQ for NSCLC
INFORMATION:
Alternate Name:
PD-L1 (SP142) TECENTRIQ
Methodology:
Immunohistochemistry
Clinical Utility:
FDA approved to predict non-small cell carcinoma (NSCLC), patient response to TECENTRIQ.
PD-L1 expression in >=50% tumor cells or >=10% tumor infiltrating immune cells as determined by this assay in NSCLC Tissue.
ORDERING:
Test Code:
TQ19-4
Turnaround Time:
HOURS
Preferred Specimen:
Formalin-fixed, Paraffin-embedded Tissue
Collection:
Container | Qty | Temp | Stability |
---|---|---|---|
Formalin-fixed, Paraffin-embedded Tissue | 1 | Room Temp |
Collection Instructions:
BLK: This comes in block form from client with surgical number imprint.
Storage Transport Instructions:
Storage/Transport Instruction: Ship with cold pack during warm weather.
Specimen Comment:
BLK: This comes in block form from client with surgical number impirint.
SLIU: This comes in unstained slide from client with Surgical number on slide.
SLIU: This comes in unstained slide from client with Surgical number on slide.
Alternative Specimen:
Unstained Slide
Billing:
CPT Codes:
88360 x 1
CPT Code Disclaimer
CPT codes provided are for informational purposes only. Accuracy of CPT presented should be validated prior to consideration for billing.
CPT coding is the sole responsibility of the billing party. Please direct any questions regarding CPT coding to the payer being billed.